News & Updates

Treatment with dalpiciclib combined with pyrotinib and endocrine therapy exhibits antitumour activity with no new safety signals in estrogen receptor (ER)-positive HER2-positive advanced breast cancer, as shown by the results of a phase II trial.

In postmenopausal women with overweight or obesity, the use of tirzepatide alongside menopause hormone therapy appears to yield better weight loss outcomes than treating with tirzepatide alone, findings from a real-world analysis have shown.

Treatment with setmelanotide results in significant BMI reductions in individuals with acquired hypothalamic obesity compared with placebo, with an acceptable safety profile, as shown by the results of a phase III study presented at ENDO 2025.